Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;100(11):1539-1556.
doi: 10.1007/s00109-022-02257-5. Epub 2022 Sep 27.

Underlying mechanisms of epithelial splicing regulatory proteins in cancer progression

Ying Liu  1   2 , Yiwen Li  3 , Chengcheng Du  3 , Shouxiang Kuang  3 , Xuehao Zhou  3 , Jinyu Zhang  3 , Xiang Ao  4   3
Affiliations
Review

Underlying mechanisms of epithelial splicing regulatory proteins in cancer progression

Ying Liu et al. J Mol Med (Berl). 2022 Nov.

Abstract

Cancer is the second-leading disease-related cause of global mortality after cardiovascular disease. Despite significant advances in cancer therapeutic strategies, cancer remains one of the major obstacles to human life extension. Cancer pathogenesis is extremely complicated and not fully understood. Epithelial splicing regulatory proteins (ESRPs), including ESRP1 and ESRP2, belong to the heterogeneous nuclear ribonucleoprotein family of RNA-binding proteins and are crucial regulators of the alternative splicing of messenger RNAs (mRNAs). The expression and activity of ESRPs are modulated by various mechanisms, including post-translational modifications and non-coding RNAs. Although a growing body of evidence suggests that ESRP dysregulation is closely associated with cancer progression, the detailed mechanisms remain inconclusive. In this review, we summarize recent findings on the structures, functions, and regulatory mechanisms of ESRPs and focus on their underlying mechanisms in cancer progression. We also highlight the clinical implications of ESRPs as prognostic biomarkers and therapeutic targets in cancer treatment. The information reviewed herein could be extremely beneficial to the development of individualized therapeutic strategies for cancer patients.

Keywords: Biomarker; CSC; EMT; ESRPs; Therapeutic target.

PubMed Disclaimer

References

    1. Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, Esener S, Fitzgerald RC, Gambhir SS, Kuhn P et al (2022) Early detection of cancer. Science 375:eaay9040. https://doi.org/10.1126/science.aay9040
    1. Wang M, Yu F, Zhang Y, Chang W, Zhou M (2022) The effects and mechanisms of flavonoids on cancer prevention and therapy: focus on gut microbiota. Int J Biol Sci 18:1451–1475. https://doi.org/10.7150/ijbs.68170 - DOI - PubMed - PMC
    1. Wang M, Chen X, Yu F, Ding H, Zhang Y, Wang K (2021) Extrachromosomal circular DNAs: origin, formation and emerging function in cancer. Int J Biol Sci 17:1010–1025. https://doi.org/10.7150/ijbs.54614 - DOI - PubMed - PMC
    1. Shan P, Yang F, Qi H, Hu Y, Zhu S, Sun Z, Zhang Z, Wang C, Hou C, Yu J et al (2021) Alteration of MDM2 by the small molecule YF438 exerts antitumor effects in triple-negative breast cancer. Cancer Res 81:4027–4040. https://doi.org/10.1158/0008-5472.CAN-20-0922 - DOI - PubMed
    1. Schumacher TN, Thommen DS (2022) Tertiary lymphoid structures in cancer. Science 375: eabf9419. https://doi.org/10.1126/science.abf9419

Publication types

MeSH terms

LinkOut - more resources